● Recruiting

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)

Condition: Locally Advanced Prostate Cancer · Oligometastatic Prostate Cancer · Sponsor: The First Affiliated Hospital of Xiamen University

PhasePhase 2

Planned participants40

Who can joinMale, 18 Years to no upper limit

Healthy volunteersNo

About this study

To evaluated the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Kaiyan Zhang, M.D. · +865922139714 · zkyken@163.com

Haichao Huang, M.D. · +865922139493 · hhc_pku@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06387056